Prospective Feasibility Pilot Study Evaluating the Value of [68Ga]Ga-PENTIXAFOR PET-CT in Patients With Metastatic Small Cell Lung Cancer (SCLC) at Diagnosis and Disease Progression

Study of LP002 in Combination With Chemotherapy for Patients With Extensive Stage Small Cell Lung Cancer

NCT04740021 ·Status: UNKNOWN ·Phase: PHASE2

89Zr-labeled Pembrolizumab in Patients With Non-small-cell Lung Cancer

NCT03065764 ·Status: UNKNOWN ·Phase: PHASE2

Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)

NCT04624204 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT07222566 ·Status: RECRUITING ·Phase: PHASE3

PH 1 Evaluation Of Oral CI-1033 In Combination With Paclitaxel/ Carboplatin As 1st Line Chemotherapy In NSCLC Patients

NCT00174356 ·Status: COMPLETED ·Phase: PHASE1

Cisplatin-Pemetrexed Compared With Carboplatin-Paclitaxel-Bevacizumab in KRAS Mutated Non-small Cell Lung Cancer

NCT02743923 ·Status: UNKNOWN ·Phase: PHASE3

Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017

NCT03003468 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Chemotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC)

NCT00391274 ·Status: COMPLETED ·Phase: PHASE3

A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma

NCT02707666 ·Status: TERMINATED ·Phase: PHASE1

Pembrolizumab for Metastatic NSCLC Patients Expressing PD-L1 Who Have Their Own PDX

NCT03134456 ·Status: COMPLETED ·Phase: PHASE4

A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)

NCT02763579 ·Status: COMPLETED ·Phase: PHASE3

Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Limited Stage Small Cell Lung Cancer

NCT00308529 ·Status: COMPLETED ·Phase: PHASE2

Identification by Microarrays of the Risks of Metastatic Relapse, Toxicity and Resistance to Adjuvant Chemotherapy in Completely Resected Non-small Cell Lung Cancer

NCT02075957 ·Status: UNKNOWN

Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer

NCT06933329 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer

NCT05364645 ·Status: WITHDRAWN ·Phase: PHASE2

A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression

NCT04274907 ·Status: TERMINATED ·Phase: PHASE1

Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)

NCT02578680 ·Status: COMPLETED ·Phase: PHASE3

Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

NCT03976323 ·Status: COMPLETED ·Phase: PHASE3

A Study of Pertuzumab With Erlotinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT02507375 ·Status: COMPLETED ·Phase: PHASE1

Locally Advanced NSCLC Treated With Radiochemotherapy: Phase 2 Study on the Value of a Stereotactic Boost

NCT06627738 ·Status: RECRUITING ·Phase: PHASE2

Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC

NCT06348797 ·Status: RECRUITING ·Phase: PHASE1

A Study in Non-Small Cell Lung Cancer

NCT01232452 ·Status: COMPLETED ·Phase: PHASE2

SCLC on the 2nd Line With Relapsed After Response to Chemotherapy GFPC 01-2013

NCT02738346 ·Status: UNKNOWN ·Phase: PHASE3

Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC

NCT04153734 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer)

NCT06822543 ·Status: RECRUITING ·Phase: PHASE2